Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06410729
Status:
COMPLETED
Last Update Posted:
2024-05-14
First Post:
2024-05-08
Brief Title:
Significance of Benign Lymph Node Enlargement in Colorectal Cancer
Sponsor:
Peking University Third Hospital
Organization:
Peking University Third Hospital
Study Overview
Official Title:
Significance of Benign Lymph Node Enlargement in Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this observational study was to investigate the clinical significance of benign mesenteric lymph node BLNE enlargement in patients with colorectal cancer The main questions it aims to answer are
Do patients with benign mesenteric lymph node enlargement have a better prognosis What are the clinical characteristics of benign mesenteric lymph node enlargement As part of routine medical care for colorectal cancer we will follow up with all participants over the course of the study
Do patients with benign mesenteric lymph node enlargement have a better prognosis What are the clinical characteristics of benign mesenteric lymph node enlargement As part of routine medical care for colorectal cancer we will follow up with all participants over the course of the study
Detailed Description:
From January 2015 to June 2023 2270 patients with colorectal cancer received surgical treatment at Peking University Third Hospital The clinical data of these patients were recorded retrospectively and the eligible patients were divided into two groups According to the 9th edition of the TNM staging System published by the AJCC the BLNE group included the mesenteric BLNE group while the non-benign lymph node enlargement NBLNE group was the control group Inclusion criteria were 1 No regional lymph node metastasis or distant metastasis 2 Stage I and II patients with AJCC staging system 3 Radical CRC resection reached R0 status no positive lymph nodes Colonoscopy confirmed a single malignant lesion Exclusion criteria 1 emergency surgery or preoperative complications such as intestinal obstruction and perforation 2 Positron emission tomography PET-CT suspected distant metastasis 3 Preoperative neoadjuvant therapy 4 Hereditary colorectal cancer such as familial adenomatous polyposis Microsatellite instability MSI was confirmed by pathology In early colorectal cancer MSI-H status is associated with a favorable prognosis and enhanced anti-tumor immune response Therefore we excluded these patients to avoid their influence on prognosis 6 Lack of imaging data 7 Loss of follow-up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None